%A Liu Xiaolan, Guan Tao, Su Liping %T Detection and clinical application of minimal residual disease in multiple myeloma %0 Journal Article %D 2018 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2018.01.013 %P 56- %V 45 %N 1 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10393.shtml} %8 2018-01-08 %X Minimal residual disease (MRD) is a very important prognostic factor in multiple myeloma (MM). The major types of MRD tests include cellbased test (multiparameter flow cytometry) and molecular tests (including PCR and gene sequencing), and the various techniques have inherent advantages and limitations. In clinical application, MRD negative can significantly prolong progressionfree survival and overall survival of patients who receive hematopoietic stem cell transplantation and conventional chemotherapy. Moreover, the MRD status is of great significance to the selection of treatment options.